Unraveling disparities: Probing gender, race, and geographic inequities in pulmonary heart disease mortality in the United States: An extensive longitudinal examination (1999–2020) leveraging CDC WONDER data

This comprehensive study delves into the epidemiological landscape of Pulmonary Heart Disease (PHD) mortality in the United States from 1999 to 2020, leveraging the extensive CDC WONDER database. PHD encompasses conditions affecting the right side of the heart due to lung disorders or elevated pressure in the pulmonary arteries, including pulmonary hypertension, pulmonary embolism, and chronic thromboembolic pulmonary hypertension (CTEPH). Analyzing data from death certificates, demographic characteristics, and geographical segmentation, significant trends emerge. The age-adjusted mortality rates (AAMRs) for PHD-related deaths show a fluctuating pattern, initially decreasing from 1999 to 2006, followed by a steady increase until 2020. Male patients consistently exhibit higher AAMRs than females, with notable disparities observed among racial/ethnic groups and geographic regions. Non-hispanic (NH) Black or African American individuals, residents of specific states like Colorado and the District of Columbia, and those in the Midwest region demonstrate elevated AAMRs. Furthermore, nonmetropolitan areas consistently manifest higher AAMRs than metropolitan areas. These findings underscore the urgent need for intensified prevention and treatment strategies to address the rising mortality associated with PHD, particularly among vulnerable populations. Insights from this study offer valuable guidance for public health initiatives aimed at reducing PHD-related mortality and improving outcomes nationwide

Synthesis of some novel norbornene-fused pyridazines as potent inhibitors of carbonic anhydrase and acetylcholinesterase

WOS:000388438000049The reaction of benzocyclic norbornene derivatives with tetrazines provided the 1,3-dihydropyridazine derivatives as a single product. The dihydropyridazine derivatives have been dehydrogenated with phenyliodine bis(trifluoroacetate) to yield the corresponding pyridazines in a high yield. Two stable diazines, primary product of corresponding 1,4-dihydropyridazine, were also isolated. Structures were then determined by H-1-NMR, and C-13-NMR beside to elemental analyses. The novel pyridazine derivatives (8-9) efficiently inhibited the cytosolic human carbonic anhydrase isoenzymes I and II (hCA I and II). In addition, these novel pyridazine derivatives (8-9) were evaluated for their in vitro acetylcholinesterase inhibitory activity. Ligand-receptor interactions are tested using molecular docking simulations. Obtained docking scores are in good agreement with in vitro results.Scientific and Technical Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [112T341]; Ataturk UniversityAtaturk University; Turkish Academy of Science, Turkey, under the BAGEP programAuthors are indebted to The Scientific and Technical Research Council of Turkey (TUBITAK, grant no. 112T341) and Ataturk University for financial supports. Thanks also to Prof. Dr Cavit Kazaz, Res. Assistant Baris Anil, Dr Murat Acar, and Res. Assistant Ufuk Atmaca for NMR experiments and elemental analyses. Additionally, S.D. acknowledges support from Turkish Academy of Science, Turkey, under the BAGEP program